Company Overview and News
2018-10-16 seekingalpha - 2
Activism in Canada is largely responsible for transportation constraints such as pipeline bottlenecks, hurting the Canadian economy in ways that Canadians could never imagine.
BTE CVE CRLFF CEI TOT ENB IMO CNI ZPTAF CHAP RRENF SNZYP TDG SN TRP IMO MEG HKRCP BP VET CVE BTE ECR USEG CHPE CP USO IKM CJ GST-A GST-B GST PTOAF WCP SCAZP HUSKF AXAS PTOAD SGY VET SPE TECK HSE AREX TDGCF CP ROSEU REI AMR MEGEF IPCFF TCKRF RRX ROSE PDS PRCYF RZREF HK SPGYF PTORF
The U.S. Energy Department's weekly inventory release showed a natural gas storage injection that fell in line with market expectations. Meanwhile, natural gas prices rallied to their highest levels since January as inventories remain significantly below their five-year average ahead of the upcoming winter.
ECR CKRGZ CNX.WI CHKVP CRK RRL RRS CHKDH CHKVZ RGRLF CHKDG CHKWZ RRC CHKDJ CHKDP RGRYY CHK CHK.WI GPOR
Larger and more financially healthy E&P companies are grouped together for analysis purposes in this "Tier One Producer" or "TOP Club"
CRC GDPMQ CHKVP PSX CRK QEP CHKVZ CRZO GDAOQ EGC EXXIQ SNZYP GDRRQ AMPY TALO SRCI EEXXQ BCEI RRS JONE WPX ESTE EXXI GDP CHK SGY TTEN MPOYQ SDRXP LINE SDRXQ APA HES DVN PVA EPE PIONF CHKDH CHKDG MCF CHKDJ ROSEU VNR CHKDP REI RSPP JNEEP AMR AMGP JAG ROSE LINEQ CKRGZ EVEP EOG RGRYY UPLMQ VNRCP PIO LNGG AR SWTF AM EXIXQ CHAP VNRBP SN XOG NBL WLL PDCE SM CTLR HKRCP SD RGRLF RRC DNR MPO VNRAP CLR GDPAN GDPAQ ECR CHPE UPL WPXP SDRPQ REN PE CXO RRL SCAZP AXAS COP AREX ECA SFY EVEPQ CDEV BRMR GDPM PVAYQ VNRR ECA SBOW CHKWZ GDUEQ SDOCQ GDANQ CHK.WI PVAC LPI WES HK HPR BRY
2018-10-08 zacks - 1
The U.S. Energy Department's weekly inventory release showed a bigger-than-expected increase in natural gas supplies. Despite the stockpile surge, natural gas prices rallied to their highest levels since January as inventories remain significantly below their five-year average ahead of the upcoming winter.
ECR CKRGZ FCN CNX.WI CHKVP CRK COG CVS CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR
2018-09-28 zacks - 1
The U.S. Energy Department's weekly inventory release showed a smaller-than-expected increase in natural gas supplies. The headline beat, which further widened the storage deficit ahead of the upcoming winter, helped the fuel to remain above the psychologically important $3 level.
ECR CKRGZ CQP CNX.WI LNG CHKVP CRK COG CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR GPN
The U.S. Energy Department's weekly inventory release showed a larger-than-expected increase in natural gas supplies. Despite the headline miss, a hefty storage deficit ahead of the upcoming winter pointed to tightening fundamentals and spurred the fuel’s price, which gained about 7.6% for the week.
ECR CKRGZ CQP LNG CHKVP CRK RDN COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR
Form 425 August 27, 2018: Eclipse Resources Corporation and Blue Ridge Mountain Resources, Inc. Merger Call FILED BY ECLIPSE RESOURCES CORPORATION PURSUANT TO RULE 425 UNDER THE SECURITIES ACT OF 1933
IRVING, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Blue Ridge Mountain Resources, Inc. (OTCPK: BRMR) (“Blue Ridge” or the “Company”) today is pleased to announce the appointment of Michael Hodges to Senior Vice President of Finance. Michael’s first day with the Company will be September 19, 2018. Effective upon the successful completion of the Company’s proposed merger with Eclipse Resources Corporation (NYSE: ECR) (“Eclipse”), Michael will assume the role of Executive Vice President and Chief Financial Officer of Eclipse from Matthew DeNezza, who is currently serving in such capacity with Eclipse.
ECR CKRGZ BRMR CHKVP SDRPQ CHKDH CHKVZ SD CHKDG CHKWZ SDOCQ CHKDJ REXX CHKDP RXNRP CHK.WI CHK REXXQ SDRXP SDRXQ
The U.S. Energy Department's weekly inventory release showed a marginally smaller-than-expected increase in natural gas supplies. Despite the headline beat and a growing storage deficit, strong production and the expected power loss from Hurricane Florence weighed on the fuel’s price, which ended flat over the week.
ECR CKRGZ CQP LNG CHKVP CRK COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR
2018-09-17 seekingalpha - 3
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ
Chicago, IL – September 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Exxon Mobil Corp. (XOM - Free Report) , Canadian Natural Resources Ltd. (CNQ - Free Report) , Suncor Energy Inc. (SU - Free Report) , TOTAL S.
ECR HLX MACK XOM ATH WTW RUSHA SU RUSHB HII CNQ ADVM AMWD SU SOI
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET